375 related articles for article (PubMed ID: 30306073)
1. Molecular basis of cystic fibrosis: from bench to bedside.
Dechecchi MC; Tamanini A; Cabrini G
Ann Transl Med; 2018 Sep; 6(17):334. PubMed ID: 30306073
[TBL] [Abstract][Full Text] [Related]
2. Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure.
Cabrini G
Mol Diagn Ther; 2019 Apr; 23(2):263-279. PubMed ID: 30478715
[TBL] [Abstract][Full Text] [Related]
3. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
4. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
5. Repairing mutated proteins--development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator.
Merk D; Schubert-Zsilavecz M
Expert Opin Drug Discov; 2013 Jun; 8(6):691-708. PubMed ID: 23574506
[TBL] [Abstract][Full Text] [Related]
6. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine.
Lopes-Pacheco M
Front Pharmacol; 2019; 10():1662. PubMed ID: 32153386
[TBL] [Abstract][Full Text] [Related]
7. Discovery and SAR of 4-aminopyrrolidine-2-carboxylic acid correctors of CFTR for the treatment of cystic fibrosis.
Scanio MJC; Searle XB; Liu B; Koenig JR; Altenbach RJ; Gfesser GA; Bogdan A; Greszler S; Zhao G; Singh A; Fan Y; Swensen AM; Vortherms T; Manelli A; Balut C; Gao W; Yong H; Schrimpf M; Tse C; Kym P; Wang X
Bioorg Med Chem Lett; 2022 Sep; 72():128843. PubMed ID: 35688367
[TBL] [Abstract][Full Text] [Related]
8. One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.
Ensinck MM; Carlon MS
Cells; 2022 Jun; 11(12):. PubMed ID: 35740997
[TBL] [Abstract][Full Text] [Related]
9. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
Solomon GM; Marshall SG; Ramsey BW; Rowe SM
Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of cystic fibrosis treatment.
Carter SC; McKone EF
Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
[TBL] [Abstract][Full Text] [Related]
11. CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis.
Lopes-Pacheco M
Front Pharmacol; 2016; 7():275. PubMed ID: 27656143
[TBL] [Abstract][Full Text] [Related]
12. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
13. Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2.
Bongiorno R; Ludovico A; Moran O; Baroni D
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629017
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule drugs for cystic fibrosis: Where are we now?
Laselva O; Guerra L; Castellani S; Favia M; Di Gioia S; Conese M
Pulm Pharmacol Ther; 2022 Feb; 72():102098. PubMed ID: 34793977
[TBL] [Abstract][Full Text] [Related]
15. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
[TBL] [Abstract][Full Text] [Related]
16. Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives.
Schmidt BZ; Haaf JB; Leal T; Noel S
Clin Pharmacol; 2016; 8():127-140. PubMed ID: 27703398
[TBL] [Abstract][Full Text] [Related]
17. Impact of
Meoli A; Eickmeier O; Pisi G; Fainardi V; Zielen S; Esposito S
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293274
[TBL] [Abstract][Full Text] [Related]
18. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
Cuyx S; De Boeck K
Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
[TBL] [Abstract][Full Text] [Related]
19. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
20. Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator.
Luciani A; Villella VR; Esposito S; Gavina M; Russo I; Silano M; Guido S; Pettoello-Mantovani M; Carnuccio R; Scholte B; De Matteis A; Maiuri MC; Raia V; Luini A; Kroemer G; Maiuri L
Autophagy; 2012 Nov; 8(11):1657-72. PubMed ID: 22874563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
